The US amdinocillin market remains a specialized segment, with demand shaped by its role as a targeted antibiotic for Gram-negative bacterial infections, particularly urinary tract infections. Although amdinocillin is not currently available in the US, its established pharmacological profile and relevance to antimicrobial treatment research continue to support interest in the drug and its...